GO:1904678 alpha-aminoacyl-tRNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904678 (alpha-aminoacyl-tRNA binding) is a molecular function term defined as binding to an alpha-aminoacyl-tRNA.
• This binding activity is central to protein synthesis, as aminoacyl-tRNAs deliver amino acids to the ribosome.
• The term is distinct from aminoacyl-tRNA synthetase activity, which charges tRNA with amino acids.
• Experimental evidence for this binding often comes from studies on tRNA interactions with drugs or other molecules.
• Dysregulation of aminoacyl-tRNA binding can impact translation fidelity and is linked to various diseases.
• Researchers can study this function using binding assays, structural biology, and CRISPR-based screens.
Description
The Gene Ontology (GO) term GO:1904678, alpha-aminoacyl-tRNA binding, describes a molecular function where a protein or other molecule selectively binds to an alpha-aminoacyl-tRNA. This interaction is fundamental to translation, as aminoacyl-tRNAs are the substrates that deliver amino acids to the ribosome for protein synthesis. Understanding this binding event is crucial for deciphering mechanisms of translation regulation and identifying potential therapeutic targets. Researchers study alpha-aminoacyl-tRNA binding to elucidate how cells maintain proteostasis and respond to stress. Moreover, this binding activity is implicated in the mechanism of action of certain drugs, such as doxorubicin, which can interact with tRNA. Thus, GO:1904678 provides a framework for investigating molecular interactions that underpin protein synthesis and its regulation.
alpha-aminoacyl-tRNA binding At A Glance
| GO ID | GO:1904678 |
|---|---|
| GO term | alpha-aminoacyl-tRNA binding |
| Ontology | molecular_function |
| Synonym | aminoacyl-tRNA binding |
| Major function | Binding to an alpha-aminoacyl-tRNA |
| Definition source | QuickGO |
| Related process | Translation |
| Related molecular function | Aminoacyl-tRNA synthetase activity |
What Is GO:1904678?
According to the Gene Ontology, GO:1904678 (alpha-aminoacyl-tRNA binding) is defined as the binding to an alpha-aminoacyl-tRNA. This means any molecular event where a protein, RNA, or other biomolecule physically associates with an aminoacyl-tRNA, which is a tRNA molecule covalently linked to its corresponding amino acid via an ester bond at the 3' end. This binding can be transient or stable and is essential for various cellular processes, particularly translation.
Why Is alpha-aminoacyl-tRNA binding Important in Cell Biology?
Alpha-aminoacyl-tRNA binding is a critical molecular function because it ensures the accurate delivery of amino acids to the ribosome during protein synthesis. This binding event is a key step in translation, and its dysregulation can lead to errors in protein production, which are associated with numerous diseases, including cancer and neurodegenerative disorders. Furthermore, understanding this binding activity can inform the development of novel therapeutics that target translation.
• Essential for translation and protein synthesis.
• Ensures fidelity of amino acid incorporation into proteins.
• Target of natural and synthetic molecules, such as doxorubicin.
• Dysregulation linked to cancer and other diseases.
• Involved in cellular stress responses.
• Potential target for antibiotic and anticancer drugs.
• Key to understanding genetic code translation.
• Relevant for synthetic biology and genetic code expansion.
• Studied using binding assays and structural techniques.
• Can be modulated by CRISPR-based gene editing.
Molecular Mechanism of alpha-aminoacyl-tRNA binding
Substrate Recognition and Binding
In simple terms: Proteins that bind aminoacyl-tRNAs must recognize the tRNA's shape and the attached amino acid.
Alpha-aminoacyl-tRNA binding typically involves specific interactions between the binding protein and the tRNA molecule, particularly the anticodon loop and the acceptor stem where the amino acid is attached. For example, elongation factor Tu (EF-Tu) binds aminoacyl-tRNA in a GTP-dependent manner to deliver it to the ribosome. The binding is highly specific to ensure the correct aminoacyl-tRNA is selected for translation.
Conformational Changes and Catalysis
In simple terms: Binding can cause shape changes in the protein or tRNA that facilitate the next steps in translation.
Upon binding, conformational changes in the protein or tRNA may occur, which can be essential for subsequent catalytic steps. For instance, aminoacyl-tRNA synthetases undergo conformational changes upon binding tRNA and amino acid to catalyze the charging reaction. However, GO:1904678 specifically refers to binding, not the catalytic activity itself.
Cofactors and Regulation
In simple terms: Other molecules like GTP or ATP can influence how proteins bind aminoacyl-tRNAs.
Many alpha-aminoacyl-tRNA binding proteins require cofactors such as GTP or ATP for optimal binding. For example, EF-Tu binds aminoacyl-tRNA in the GTP-bound state, and hydrolysis of GTP to GDP leads to release of the tRNA at the ribosome. This regulation ensures that translation proceeds efficiently and accurately.
Binding Specificity and Proofreading
In simple terms: Cells have mechanisms to ensure only the correct aminoacyl-tRNA is used, preventing errors.
Binding specificity is crucial for translational fidelity. Some aminoacyl-tRNA synthetases have proofreading domains that hydrolyze incorrectly charged tRNAs. Additionally, the ribosome itself monitors the match between codon and anticodon during aminoacyl-tRNA selection. These quality control mechanisms rely on precise binding interactions.
Interaction with Drugs and Small Molecules
In simple terms: Certain drugs can bind to tRNA or aminoacyl-tRNA, interfering with translation.
Doxorubicin, an anticancer drug, has been shown to bind to tRNA and potentially to aminoacyl-tRNA, which may contribute to its antitumor activity. Structural models suggest that doxorubicin intercalates into tRNA, disrupting its function. This highlights the potential of targeting alpha-aminoacyl-tRNA binding for therapeutic intervention.
Key Genes Involved in GO:1904678 alpha-aminoacyl-tRNA binding
The following genes encode proteins that are known or predicted to exhibit alpha-aminoacyl-tRNA binding activity, based on their roles in translation and related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AARS1 | Alanyl-tRNA synthetase; charges tRNA with alanine | Mutations cause Charcot-Marie-Tooth disease; target for binding studies |
| AARS2 | Mitochondrial alanyl-tRNA synthetase | Associated with mitochondrial disorders |
| CARS1 | Cysteinyl-tRNA synthetase | Involved in protein synthesis; potential drug target |
| DARS1 | Aspartyl-tRNA synthetase | Mutations linked to hypomyelination |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase | Component of multi-synthetase complex |
| FARSA | Phenylalanyl-tRNA synthetase alpha subunit | Role in translation; potential cancer target |
| GARS1 | Glycyl-tRNA synthetase | Mutations cause Charcot-Marie-Tooth disease |
| HARS1 | Histidyl-tRNA synthetase | Associated with Usher syndrome |
| IARS1 | Isoleucyl-tRNA synthetase | Involved in translation; potential disease links |
| KARS1 | Lysyl-tRNA synthetase | Mutations cause neuropathy |
| LARS1 | Leucyl-tRNA synthetase | Regulator of mTORC1; disease associations |
| MARS1 | Methionyl-tRNA synthetase | Mutations cause interstitial lung disease |
| NARS1 | Asparaginyl-tRNA synthetase | Associated with neurodegeneration |
| QARS1 | Glutaminyl-tRNA synthetase | Mutations cause progressive microcephaly |
| RARS1 | Arginyl-tRNA synthetase | Mutations cause hypomyelination |
| SARS1 | Seryl-tRNA synthetase | Involved in translation; disease links |
| TARS1 | Threonyl-tRNA synthetase | Mutations cause neuropathy |
| VARS1 | Valyl-tRNA synthetase | Mutations cause neurodevelopmental disorder |
How Is alpha-aminoacyl-tRNA binding Regulated?
The binding of alpha-aminoacyl-tRNAs is regulated at multiple levels. Aminoacyl-tRNA synthetases are regulated by post-translational modifications and interactions with other proteins. The availability of aminoacyl-tRNAs is controlled by the activity of these synthetases and by tRNA abundance. Additionally, signaling pathways such as mTORC1 sense amino acid levels and regulate translation initiation and elongation, indirectly affecting aminoacyl-tRNA binding. In response to stress, the integrated stress response (ISR) can phosphorylate eIF2α, reducing ternary complex formation and thus aminoacyl-tRNA delivery to the ribosome.
alpha-aminoacyl-tRNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GARS1 | Charcot-Marie-Tooth disease | Knockout mice, patient-derived iPSCs |
| AARS1 | Charcot-Marie-Tooth disease | Point mutation knock-in mice |
| DARS1 | Hypomyelination with brainstem and spinal cord involvement | Knock-in mouse models |
| KARS1 | Neuropathy | CRISPR knockout cell lines |
| LARS1 | Infantile liver failure syndrome | Patient fibroblasts, knockout models |
Cancer
Dysregulation of translation and aminoacyl-tRNA binding is frequently observed in cancer. Doxorubicin, a chemotherapeutic agent, binds to tRNA and may interfere with aminoacyl-tRNA binding, contributing to its antitumor activity. Additionally, overexpression of certain aminoacyl-tRNA synthetases has been linked to cancer progression.
Neurodegenerative Disorders
Mutations in genes encoding aminoacyl-tRNA synthetases, which are involved in aminoacyl-tRNA binding, cause various neurodegenerative diseases such as Charcot-Marie-Tooth disease and hypomyelination. These mutations often impair tRNA charging and binding, leading to protein synthesis defects in neurons.
Mitochondrial Diseases
Mitochondrial aminoacyl-tRNA synthetases are essential for mitochondrial translation. Mutations in these genes can cause severe mitochondrial disorders, often affecting tissues with high energy demands. The binding of aminoacyl-tRNAs within mitochondria is critical for oxidative phosphorylation.
From alpha-aminoacyl-tRNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X bind aminoacyl-tRNA? | In vitro binding assays (EMSA, SPR) |
| What is the effect of a disease-associated mutation on binding? | Point mutation knock-in cell lines |
| Can we rescue a disease phenotype by restoring binding? | Knock-in of wild-type gene |
| Which genes are essential for translation? | CRISPR knockout library screening |
| How does overexpression of gene X affect translation? | Overexpression cell models |
| Where does binding occur in the cell? | Tagged knock-in for imaging |
How to Study the alpha-aminoacyl-tRNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EMSA | Binding affinity and specificity | In vitro validation of protein-tRNA interactions |
| SPR | Kinetic constants (kon, koff) | Quantitative binding studies |
| X-ray crystallography | 3D structure of complexes | Atomic-level details of binding |
| Cryo-EM | Structures of large complexes | Ribosome-tRNA interactions |
| Ribo-seq | Translation efficiency and codon occupancy | Global translation profiling |
| CRISPR screen | Gene essentiality and fitness | Identification of novel binding regulators |
| RNA-seq | Gene expression changes | Transcriptional response to binding perturbations |
Binding Assays
Electrophoretic mobility shift assays (EMSA) and surface plasmon resonance (SPR) are commonly used to measure the binding affinity between proteins and aminoacyl-tRNAs. These techniques can determine kinetic parameters and specificity.
Structural Biology
X-ray crystallography and cryo-electron microscopy (cryo-EM) provide high-resolution structures of protein-tRNA complexes, revealing the molecular details of alpha-aminoacyl-tRNA binding. For example, structural models of doxorubicin-tRNA complexes have been proposed.
Ribosome Profiling
Ribo-seq (ribosome profiling) captures ribosome-protected mRNA fragments, offering a snapshot of translation at codon resolution. It can reveal defects in aminoacyl-tRNA binding that affect translation elongation.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes required for aminoacyl-tRNA binding and translation. Such screens have uncovered essential components of the translation machinery.
How CRISPR Can Be Used to Study GO:1904678 alpha-aminoacyl-tRNA binding
Knockout
CRISPR knockout of genes encoding aminoacyl-tRNA synthetases or binding proteins can abolish alpha-aminoacyl-tRNA binding, leading to translation defects. Such models are valuable for studying the essentiality of these genes and for identifying compensatory pathways.
Point Mutation
Introducing disease-associated point mutations into genes involved in aminoacyl-tRNA binding via CRISPR can recapitulate human pathologies in cell or animal models. These models help dissect the molecular consequences of impaired binding.
Knock-in
Knock-in of tagged versions of binding proteins (e.g., GFP or HA) allows for visualization and purification of complexes. This approach is useful for studying localization and interaction partners of alpha-aminoacyl-tRNA binding proteins.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase levels of aminoacyl-tRNA binding proteins, enabling studies of dosage effects on translation and cell fitness.
How EDITGENE Supports alpha-aminoacyl-tRNA binding Research
Researchers studying alpha-aminoacyl-tRNA binding-related genes often need to determine whether a candidate gene is causally involved in translation regulation, disease pathogenesis, or drug response. EDITGENE provides a comprehensive suite of CRISPR services to facilitate these investigations.
Contact EDITGENE today to design your custom CRISPR model for alpha-aminoacyl-tRNA binding research.
Frequently Asked Questions About alpha-aminoacyl-tRNA binding
What is alpha-aminoacyl-tRNA binding?
Alpha-aminoacyl-tRNA binding is a molecular function (GO:1904678) defined as the binding to an alpha-aminoacyl-tRNA, a tRNA molecule linked to its corresponding amino acid.
What genes are involved in alpha-aminoacyl-tRNA binding?
Genes encoding aminoacyl-tRNA synthetases (e.g., AARS1, GARS1, MARS1) and translation factors (e.g., EEF1A1) are involved in alpha-aminoacyl-tRNA binding.
How is alpha-aminoacyl-tRNA binding studied?
It is studied using binding assays (EMSA, SPR), structural biology (X-ray crystallography, cryo-EM), and functional assays like Ribo-seq.
What diseases are associated with defects in alpha-aminoacyl-tRNA binding?
Defects can cause Charcot-Marie-Tooth disease, hypomyelination, mitochondrial disorders, and cancer.
What is the difference between aminoacyl-tRNA binding and aminoacyl-tRNA synthetase activity?
Aminoacyl-tRNA binding is the physical interaction with an already charged tRNA, while synthetase activity catalyzes the charging reaction.
Can CRISPR be used to study alpha-aminoacyl-tRNA binding?
Yes, CRISPR knockout, knock-in, and point mutation models can be used to study the function of genes involved in this binding.
What is the role of alpha-aminoacyl-tRNA binding in translation?
It ensures the correct aminoacyl-tRNA is delivered to the ribosome for protein synthesis.
How does doxorubicin interact with tRNA?
Doxorubicin can bind to tRNA, potentially interfering with aminoacyl-tRNA binding and translation.
What are the research methods for alpha-aminoacyl-tRNA binding?
Common methods include EMSA, SPR, X-ray crystallography, cryo-EM, Ribo-seq, and CRISPR screens.
Why is alpha-aminoacyl-tRNA binding important for drug discovery?
It is a target for antibiotics and anticancer drugs, as interfering with this binding can inhibit translation.
Conclusion
Alpha-aminoacyl-tRNA binding (GO:1904678) is a fundamental molecular function that underpins protein synthesis and is implicated in a range of human diseases. Understanding its mechanisms and regulation offers insights into translation control and provides opportunities for therapeutic intervention. Researchers can leverage CRISPR-based models and advanced screening techniques to dissect the roles of specific genes and mutations in this process.
References
- 1. Davis MW et al.. 1977. Ski injuries.. J Trauma 17(10):802-8 PMID: 909122
- 3. Agudelo D et al.. 2016. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity.. J Photochem Photobiol B 158:274-9 PMID: 26971631
